Hepatitis is an inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer. Hepatitis can be caused by infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases .There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread.
Why I3T Focuses on that:
An inflammation in liver leading to damage and dysfunction of the organ is named as ‘Hepatitis’. Attributes are manifold e.g. heavy alcohol consumption, toxic chemical or medicine abuse, autoimmune dysregulations etc. but the viral hepatitis brought about by one of the viruses: hepatitis A, B, C, D or E remains the most common reason. It is an immense burden on the individual as well as on the public health. Hepatitis B, C and alcoholic hepatitis have been recently identified to contribute very substantially to the global burden of liver cirrhosis in terms of the disability-adjusted life-year (DALY), World Health Organization (WHO)’s metric of public health burden. Financially weak countries have reportedly born the heaviest load of cirrhosis burden primarily rooted to hepatitis B infection since years. Non-alcoholic fatty liver associated with increasing prevalence of obesity has recently emerged as dominant cause of liver fibrotic scars along with alcohol and hepatitis C in opulent countries. The case count for chronic hepatitis B and C infection was estimated to be about 40 million and 6-12 million respectively in 2020 by WHO. These data along with the record of approximately 250000 deaths per year reflect the severity of hepatitis as a potent public health threat in India.
In I3TK, we aim to pursue applicative research on unravelling novel host-virus interaction, molecular mechanism of suppression of infection, crosstalk between cellular pathways to mediate alcoholic as well as non-alcoholic hepatitis, correlation of fatty liver with other metabolic syndrome to achieve appropriate clinical data prediction, end-point therapy, and sustainable disease management.